Truist Securities Downgrades Treace Medical Concepts Inc (TMCI) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Morgan Stanley Downgrades Treace Medical Concepts Inc (TMCI) to Equalweight
May 8, 2024 9:30 AM EDTMorgan Stanley analyst Drew Ranieri downgraded Treace Medical Concepts Inc (NASDAQ: TMCI) from Overweight to Equalweight with a price target of $5.50 (from $15.00).
The analyst comments "Competitive disruptions are hitting Treace's commercial momentum with the company now playing innovation catch up, lowering our... More
Stifel Downgrades Treace Medical Concepts Inc (TMCI) to Hold
May 8, 2024 6:03 AM EDTStifel analyst Rick Wise downgraded Treace Medical Concepts Inc (NASDAQ: TMCI) from Buy to Hold with a price target of $6.00 (from $15.00).
The analyst comments "We are downgrading TMCI to Hold and lowering our price target to $6 from $15, as multiple increasing competitive headwinds have added incremental... More
BTIG Downgrades Treace Medical Concepts Inc (TMCI) to Neutral
May 8, 2024 5:26 AM EDTBTIG analyst Ryan Zimmerman downgraded Treace Medical Concepts Inc (NASDAQ: TMCI) from Buy to Neutral.
The analyst comments "We are downgrading TMCI shares to Neutral and removing our PT following TMCI's 1Q24 results. Quarterly results were fine as TMCI reported rev. of $51.1M (21.1% Y/Y), above BTIG/Consensus est. of $49.1M/$49.1M as a seasonally strong 4Q extended into the early part of the year. However, increasing pressure from competitors offering osteotomy-specific... More
JPMorgan Downgrades Treace Medical Concepts Inc (TMCI) to Neutral
May 8, 2024 5:01 AM EDTJPMorgan analyst Robbie Marcus downgraded Treace Medical Concepts Inc (NASDAQ: TMCI) from Overweight to Neutral with a price target of $8.00 (from $15.00).
The analyst comments "Treace reported a disappointing update after the close on Tuesday as a good quarter came alongside a significant cut to guidance due to growing competitive headwinds. Starting with the quarter, sales of $51.1M (+21%) came... More
Treace Medical Concepts, Inc. (TMCI) Misses Q1 EPS by 3c, Beats on Revenue; Lowers FY24 Revenue Guidance
May 7, 2024 4:25 PM EDTTreace Medical Concepts, Inc. (NASDAQ: TMCI) reported Q1 EPS of ($0.30), $0.03 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $51.1 million versus the consensus estimate of $49.07 million.
GUIDANCE:
Treace Medical Concepts, Inc. lowers guidance range for full-year 2024, expecting... More
